Shots:
- Charles River Laboratories to acquire Vigene in all cash transaction for $292.5M. In addition to the initial purchase price, the transaction includes contingent additional payments of up to $57.5M based on future performance
- The transaction is expected to be close in Q3’21. The acquisition will allow Charles River to boost its gene therapy capabilities in the high-growth, value-added cell, and gene therapy CDMO sector
- Vigene is expected to improve Charles River’s reported revenue growth rate by ~50 basis points in 2021. The acquisition complements Charles River’s existing non-clinical development and manufacturing portfolio
Click here to read full press release/ article | Ref: Business Wire | Image: Pharma Advancement
The post Charles River to Acquire Vigene Biosciences for $292.5M first appeared on PharmaShots.
